Charles E. Triano | Pfizer Inc. |
Ian C. Read | Pfizer Inc. |
Frank A. D'Amelio | Pfizer Inc. |
Albert Bourla | Pfizer Inc. |
Mikael Dolsten | Pfizer Inc. |
John D. Young | Pfizer Inc. |
Douglas M. Lankler | Pfizer Inc. |
Umer Raffat | Evercore ISI |
Christopher Schott | JPMorgan Securities LLC |
Andrew S. Baum | Citigroup Global Markets Ltd. |
Gregg Gilbert | Deutsche Bank Securities, Inc. |
David Maris | Wells Fargo Securities LLC |
Jami Rubin | Goldman Sachs & Co. LLC |
Seamus Fernandez | Leerink Partners LLC |
Vamil K. Divan | Credit Suisse Securities (NYSE:USA) LLC |
David R. Risinger | Morgan Stanley & Co. LLC |
Tim Anderson | Sanford C. Bernstein & Co. LLC |
John T. Boris | SunTrust Robinson Humphrey, Inc. |
Richard J. Purkiss | Piper Jaffray Ltd. |
Steve Scala | Cowen and Co. LLC |
Alex Arfaei | BMO Capital Markets (United States) |
Marc Goodman | UBS Securities LLC |
Olivia Brayer | Guggenheim Securities LLC |
Jeffrey Holford | Jefferies LLC |
Geoffrey Meacham | Barclays Capital, Inc. |
Good day, everyone, and welcome to Pfizer's third quarter 2017 earnings conference call. Today's call is being recorded. At this time, I would like to turn the call over to Mr. Chuck Triano, Senior Vice President of Investor Relations. Please go ahead, sir.